UNSPSC 51434935: Hydralazine/hydrochlorothiazide/reserpine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434935 Hydralazine/hydrochlorothiazide/reserpine is a Commodity code representing specific combination-therapy hypertension medications; in practice, state and local governments buy emergency medical services medications, generic multi-source pharmaceuticals, and over-the-counter products more broadly under pharmaceutical procurement activity at this tier. Recent solicitations show municipal fire rescue departments, state health agencies, and multistate cooperative purchasing alliances acquiring Advanced Life Support medications (epinephrine, adenosine, diltiazem, labetalol), generic pharmaceuticals through authorized wholesalers, and OTC products for distributed public facilities. Issuing bodies include city procurement offices, state health and human services commissions, and multistate cooperative purchasing vehicles. The City of Tampa Fire Rescue and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent direct end-user demand and aggregated procurement infrastructure, respectively.

Geographic activity centers on Florida and Minnesota, with multistate reach through cooperative purchasing. The City of Tampa issued an IFB (Bid No. 26-P-00188) for Advanced Life Support Medications due April 8, 2026, with an estimated contract value of $40,000 and a one-year initial term plus renewal options; Tampa Fire Rescue specified four medication line items totaling over 3,500 units, requiring nine-month minimum expiration dating and ten-day delivery. The Minnesota Department of Administration issued an RFP through MMCAP for generic multi-source pharmaceuticals and OTC products due March 26, 2026, with contract effectiveness July 1, 2026 and a two-year initial term; vendors must contract with at least two of three authorized wholesalers and hold comprehensive insurance including $5 million commercial general liability and $2 million network security liability. The Texas Health and Human Services Commission issued an RFI on direct-to-manufacturer prescription programs (due April 3, 2026) to gather vendor capability intelligence for a future formal solicitation. All opportunities require FDA compliance, current Good Manufacturing Practices certification, and compliance with the Drug Supply Chain Security Act.